tirzepatide cvot Tirzepatide and Heart Rate: Clinical Effects and Monitoring

How the weight loss drug tirzepatide is also helping heart failure patients

20.06

★★★★☆4.8 (126)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

23.28

★★★★★4.9 (98)

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx

25.92

★★★★★5.0 (157)

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program | Cardiovascular Diabetology

21.89

★★★★★4.7 (84)

At a glance factsheet: Tirzepatide for management of type 2 diabetes

20.17

★★★★★4.9 (203)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

27.47

★★★★★5.0 (176)

New SURPASS-CVOT Ad Hoc Analysis: Tirzepatide outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound

23.15

★★★★★4.8 (132)